Cantargia – executive interview

Published on 16 March 2022

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme; the most advanced indications are pancreatic cancer and non-small cell lung cancer. CAN10, the second lead asset, is being developed for systemic sclerosis and myocarditis, with clinical development expected to start in 2022. In this video, the company’s chief executive officer Göran Forsberg provides an update on R&D progress and the upcoming newsflow.

Share this with friends and colleagues